The Global Non-Oncology Precision Medicine Market to Reach $129.96 Billion by 2030, reports BIS Research

The global non-oncology precision medicine market is projected to reach $129.96 billion by 2030, reveals a premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 11.03% during the period 2020-2030.

The comprehensive study of the non-oncology precision medicine market by BIS Research extensively covers the following:

• Market numbers on micro-segments that are influencing the market
• More than 1500 products present in the market
• Market share analysis of more than 20 companies
• Detailed global and regional market share analysis including the scrutiny of more than 15 countries
• Study of data of more than 50 companies

View the Report from BIS Research : https://bisresearch.com/industry-report/non-oncology-precision-medicine-market.html

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and brief analysis of available technologies and FDA approved personalized therapies in each application in the last three years.

BIS Research study indicates that the increasing number of precision diagnostics and therapeutics in demand, rising reliability for polymerase chain reaction (PCR) and next-generation sequencing (NGS) results, the rising prevalence of infectious diseases globally, and improving awareness among othersare propelling factors for the growth of the market.

The study also highlights the various emerging opportunities for the market, such as the increasing number of FDA approvals for personalized medicines and expanding research collaborations. The market intelligence report by BIS Research additionally throws a spotlight on the key industry drivers that are expected to have a humungous influence in shaping the industry in the future. Some of these drivers include the reducing trial and error based prescription due to precision medicine methodology, decreasing overall cost of genetic sequencing, and the rising prevalence of chronic disorders.

In order to gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include ecosystem and application analysis, types of products offered, technologies used, sources used, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The ecosystem and application analysis of the global market includes data analysis on the satisfaction level of different products such as kits, consumables, and instruments offered, and the pricing analysis of such products. The study is majorly centered on the sub-segments and micro-segments of the different product markets and their technologies.

Emphasizing the dominance of North America among all the regions market in 2020 and 2030, Nitish Kumar Singh, Principal Analyst – BIS Research, states, "The North-America region accounted for the largest share among all the regions, holding 41.21% of the non-oncology precision medicine market in 2019. This segment is anticipated to grow at a CAGR of 9.57% during the forecast period 2020-2030. However, it is expected that the Asia-Pacific region will witness the highest CAGR of 14.11% during the forecast period, 2020-2030.”

Request for a Sample: https://bisresearch.com/requestsample?id=998&type=download

Key insights have been drawn from in-depth interviews with the key opinion leaders of more than 50 leading companies, market participants, and vendors. The key players profiled in the report include Abbott Laboratories, Agilent Technologies, Inc., Asuragen, Inc., Almac Group, AstraZeneca PLC, Bristol Myers Squibb, bioMérieux SA., BGI, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, Danaher Corp., GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc., Invitae Corporation, Opko Health, Inc., Laboratory Corporation of America Holdings, Pacific Biosciences of California, Inc., Partek Incorporated, Randox Laboratorie, Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics.

The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?
• Manufacturers of instruments, kits, assays, targeted therapies, drugs, and consumables
• Providers of laboratory-developed diagnostic tests
• Companies in the services market of genetic testing
• Research firms investing in precision therapies

How can market intelligence on non-oncology precision medicine add value to an organization’s decision-making process?
• Aids in product development
• Helps in targeting a segment for launching a new product
• Offers go-to-market strategies for the different source type
• Supports in diversifying the product portfolio basis risk and progression of technology (sequencing, microarray, PCR)
• Helps in analyzing technological substitutes and compares the specification
• Aids in understanding the strategies opted by the key players
• Assists in exploring the newer application
• Supports in analyzing the competitors’ funding scenario
• Aids in identifying an unexplored segment of therapeutics with less number of available personalized treatment
Insightful Questions Covered to Enable Companies to take Strategic Decisions

• What are the different types of technologies available in the non-oncology precision medicine market, and what are the benefits offered by them?
• What are the key development strategies implemented by the key players to stand out in this market?
• What are the emerging technologies that can take over the current technologies for molecular diagnosis within the non-oncology precision medicine market?
• How have the strategic collaborations among the key players and academia provided a push to product development within the non-oncology precision medicine market?
• Which technology has witnessed maximum adoption in terms of patent filing and development of molecular therapeutics within the market, and why?
• What are the regulations pertaining to the global non-oncology precision medicine market in different regions?
• What are the initiatives implemented by different government bodies regulating the development and commercialization of non-oncology precision medicine products and associated platforms?
• How has COVID-19 impacted the non-oncology precision medicine market?
• How will the urgency of the pandemic influence the global non-oncology precision medicine market?
• What are the leading companies dominating the global non-oncology precision medicine market?
• What are the significant research and developmental investments performed by the key market players?
• What is the reimbursement scenario of the products offered in the global non-oncology precision medicine market?
• Based on the application area, which global non-oncology precision medicine market application area is anticipated to witness a massive rise in demand in the forecast period?
• How is each segment of the global non-oncology precision medicine market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?

BIS Research Related Market Studies:

https://bisresearch.com/industry-report/global-precision-medicine-market.html

Contact:
Bhavya Banga
Email: media@bisresearch.com
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
Visit our Blog @ https://blog.bisresearch.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch

About BIS Research:
BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as custom studies, and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.

BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, Precision Medicine, and other emerging healthcare technologies, covering the entire industry spectrum. In the past five years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform for the past two years successfully.

This release was published on openPR.